TCRR News and Press, TCR2 Therapeutics Inc. From 01/19/21

TCR2 Therapeutics  ([[TCRR]] -0.4%) commences an underwritten public offering of $125M of shares of common stock.Underwriter's option to purchase up to an additional $18.75M shares.Actual size and terms yet to be finalised.Company intends to use the net proceeds to advance its ...

TCR2 Therapeutics (TCRR) launches public offering of $125M of common shares with underwriters' option to purchase up to an additional $18.75M shares. Net proceeds will be used to advance its clinical and earlier stage programs and for research and development, working capital and general corp...

Clinical-stage immunotherapy company TCR2 Therapeutics (TCRR) lays out clinical data and regulatory milestones for the year, and predicts development of three product candidates in to clinical trials in 2021.Data from its phase-1 Gavo-cel study testing TRuC-T cell targeting mes...

- Additional data from ongoing gavo-cel Phase 1/2 trial to be presented in 1H21 - Identification of gavo-cel recommended Phase 2 dose and initiation of Phase 2 study expected in 2021 - Initial data from ongoing TC-110 Phase 1/2 trial anticipated in 2021 - IND for third program...

CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Garry Menzel, Ph.D., President and Chief Executive Office...

Prevail Therapeutics (PRVL) +84% on being acquired by Lilly for ~$1.04B.OncoCyte Corporation (OCX) +63% after company enters agreement with Burning Rock Biotech.Anavex Life Sciences (AVXL) +40% as it's blarcamesine successful in mid-stage rett syndrome study.Mid-Con Energy Part...

TCR2 Therapeutics (TCRR) announces positive interim data from the ongoing Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors.TC-210 induced tumor regression in all of the first eight patients and ovarian cancer patient achieved confirmed RE...

Aerpio Pharmaceuticals ARPO -43% after announcing results from Razuprotafib Glaucoma Phase 2 Trial.Greenwich LifeSciences (GLSI) -18%.Gamida Cell (GMDA) -18% on providing regulatory update on biologics license application for Omidubicel.Virgin Galactic Holdings SPCE -...

- TC-210 induced tumor regression in all of the first eight patients - Ovarian cancer patient achieved confirmed RECIST partial response (PR) - Overall response rate (ORR) 50% in patients infused with TC-210 and lymphodepletion - Continued manageable toxicity profile - Pha...

Gainers: [[TCRR]] +28.7%. [[NSCO]] +15.8%. [[DBX]] +9.2%. [[DPW]] +4%.  [[GIK]] +3.2%.Losers: [[MYGN]] -8.6%. [[IMAB]] -6%. [[TPGY]] -5%. [[MDLY]] -4%. [[AIV]] -3.9%. For further details see: DBX, MYGN, DPW and AIV among after-hours movers